Chua, Winnie
Cardoso, Victor R.
Guasch, Eduard
Sinner, Moritz F.
Al-Taie, Christoph
Brady, Paul
Casadei, Barbara
Crijns, Harry J. G. M.
Dudink, Elton A. M. P.
Hatem, Stéphane N.
Kääb, Stefan
Kastner, Peter
Mont, Lluis
Nehaj, Frantisek
Purmah, Yanish
Reyat, Jasmeet S.
Schotten, Ulrich
Sommerfeld, Laura C.
Zeemering, Stef
Ziegler, André
Gkoutos, Georgios V.
Kirchhof, Paulus
Fabritz, Larissa
Article History
Received: 24 October 2022
Accepted: 8 September 2023
First Online: 5 October 2023
Competing interests
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare: LF has received institutional research grants and non-financial support from European Union, British Heart Foundation, Medical Research Council (UK), DFG, German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK) and several biomedical companies. PKi has received additional support for research from the European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Heart Research, from several drug and device companies active in atrial fibrillation, honoraria from several such companies. PKi and LF are listed as inventors on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). PKa is an employee of Roche Diagnostics GmbH. AZ is an employee of Roche Diagnostics Intl. All other authors have reported no other relationships or activities that could appear to have influenced the submitted work.